147 related articles for article (PubMed ID: 35574359)
1. Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study.
Zhang J; Zhang Q; Liu Z; Wang J; Shi F; Su J; Wang T; Wang F
Front Oncol; 2022; 12():877155. PubMed ID: 35574359
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.
Zhang Q; Zhang J; Liu Z; Wang J; Wang F; Wang T; Shi F; Su J; Zhao Y
Drug Des Devel Ther; 2023; 17():3507-3522. PubMed ID: 38046281
[TBL] [Abstract][Full Text] [Related]
3. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.
Yi L; Ning Z; Xu L; Shen Y; Zhu X; Yu W; Xie J; Meng Z
ESMO Open; 2024 Feb; 9(2):102239. PubMed ID: 38325225
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study.
Wang B; Zhong C; Liao Z; Wang H; Cai X; Zhang Y; Wang J; Wang T; Yao H
Thorac Cancer; 2023 Oct; 14(30):3051-3057. PubMed ID: 37675621
[TBL] [Abstract][Full Text] [Related]
5. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
Lin XJ; Li QJ; Lao XM; Yang H; Li SP
BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.
Zhang Y; Qian L; Chen K; Gu S; Wang J; Meng Z; Li Y; Wang P
Mol Ther Oncolytics; 2022 Jun; 25():31-42. PubMed ID: 35399603
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.
Gao P; Ding G; Wang L
Transl Cancer Res; 2021 Oct; 10(10):4290-4302. PubMed ID: 35116288
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
Lu W; Zheng S; Li XF; Huang JJ; Zheng X; Li Z
World J Gastroenterol; 2004 Dec; 10(24):3634-8. PubMed ID: 15534920
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer.
Zhang X; Wang Y; Lv X; Wang F; Zhou Q; Zhang F; Zhang M; Chen J
Int J Gynecol Cancer; 2023 Jul; 33(7):1051-1056. PubMed ID: 37208018
[TBL] [Abstract][Full Text] [Related]
13. A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study.
Zhang R; Cui Y; Guan X; Jiang X
Front Oncol; 2021; 11():752504. PubMed ID: 34956877
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenovirus H101 Synergizes with Radiation in Cervical Cancer Cells.
Duan Y; Bai H; Li X; Wang D; Wang Y; Cao M; Zhang N; Chen H; Wang Y
Curr Cancer Drug Targets; 2021; 21(7):619-630. PubMed ID: 33687882
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effects of oncolytic adenovirus H101 against lung cancer.
Lei J; Li QH; Yang JL; Liu F; Wang L; Xu WM; Zhao WX
Int J Oncol; 2015 Aug; 47(2):555-62. PubMed ID: 26081001
[TBL] [Abstract][Full Text] [Related]
20. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
